

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), FITC-

General Information

Synonyms: NS3;KRAS;KRAS1;CFC2;RALD;KRAS2;C-K-RAS;GTPase Kras;NS;K-RAS2B;MHC;KI-RAS;RASK2;K-RAS4A;K-Ras 2;K-RAS4B;K-RAS2A

Protein Construction: Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVGAVGVGK peptide

Species: Human

Expression Host: E. coli

Accession: AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVGAVGVGK

Molecular Weight: 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M)

QC Testing

Biological Activity: Activity has not been tested. It is theoretically active, but we cannot guarantee it.

Purity: > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC

Formulation: Supplied as 0.22 µm filtered solution in 20 mM Tris, 200 mM NaCl (pH 8.0).

Preparation and Storage

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481